+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of a medicine called survodutide on adults living with type 2 diabetes who have a body mass index BMI of 23 kgm2 or higher. The study aims to find out whether survodutide helps control blood sugar levels compared to a placebo. This phase III trial includes participants who manage their diabetes with diet and exercise, diabetes tablets, or insulin injections, reflecting different treatment backgrounds. Participants are divided into three parts based on their current diabetes treatment Part A includes those using diet and exercise only, Part B includes those on oral diabetes medications without insulin, and Part C includes those using insulin injections with or without diabetes tablets. Within each part, participants are randomly assigned to one of three groups placebo, low-dose survodutide, or high-dose survodutide. The medicine or placebo is injected under the skin once a week while participants continue their regular diabetes treatment. Over about 14 months, participants attend up to 12 in-person visits and receive at least 9 phone calls for monitoring. Doctors regularly check blood sugar levels using HbA1c tests and other laboratory tests, and monitor overall health and any changes. The main measure is the change in HbA1c from the start to Week 41, while additional outcomes include blood sugar levels, body weight, cholesterol, kidney function, and insulin dose changes. Results will compare survodutide groups with placebo to assess its impact on diabetes management.

Age: 18Years +All GendersPhase 3
101 locations